Larvol Delta - Cumulative-Days-of-Musculoskeletal-Improvement-in-BioNa239ve-Patients-With-PsA-With-or-Without-Metabolic-Syndrome-and-Obesity-Receiving-Risankizumab-Through-Week-244-Integrated-Results-From-the-KEEPsAKE-Clinical-Trials

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1899283&mode=presInfo

Saakshi Khattri, MD,MBBS

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next